GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Verastem Inc (FRA:2VSA) » Definitions » Buyback Yield %

Verastem (FRA:2VSA) Buyback Yield % : 0.00 (As of Nov. 28, 2024)


View and export this data going back to 2012. Start your Free Trial

What is Verastem Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Verastem's current buyback yield was 0.00%.


Verastem Buyback Yield % Historical Data

The historical data trend for Verastem's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verastem Buyback Yield % Chart

Verastem Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Buyback Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.06 -29.60 -1.56 -45.50 -44.81

Verastem Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.93 - - - -

Competitive Comparison of Verastem's Buyback Yield %

For the Biotechnology subindustry, Verastem's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Verastem's Buyback Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Verastem's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Verastem's Buyback Yield % falls into.



Verastem Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Verastem's Buyback Yield for the fiscal year that ended in Dec. 2023 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 83.832) / 187.08088
=-44.81%

Verastem's annualized Buyback Yield for the quarter that ended in Sep. 2024 is calculated as

Buyback Yield=Net Issuance of Stock(Annualized) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) * Annualized Factor / Market Cap
=- (0 + 0) * 4 / 100.655
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the annualized quarterly data, the Repurchase of Stock and Issuance of Stock data used here is four times the quarterly (Sep. 2024) data.


Verastem Buyback Yield % Related Terms

Thank you for viewing the detailed overview of Verastem's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Verastem Business Description

Traded in Other Exchanges
Address
117 Kendrick Street, Suite 500, Needham, MA, USA, 02494
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.

Verastem Headlines

No Headlines